Assuntos
Fármacos Anti-HIV/provisão & distribuição , COVID-19/epidemiologia , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , Pandemias , Angola/epidemiologia , Fármacos Anti-HIV/uso terapêutico , Centers for Disease Control and Prevention, U.S./organização & administração , HIV-1/efeitos dos fármacos , Humanos , Namíbia/epidemiologia , SARS-CoV-2/patogenicidade , Viagem/estatística & dados numéricos , Estados UnidosRESUMO
Namibia is an upper-middle income country in southern Africa, with a population of approximately 2.5 million (1). On March 13, 2020, the first two cases of coronavirus disease 2019 (COVID-19) in Namibia were identified among recently arrived international travelers. On March 17, Namibia's president declared a state of emergency, which introduced measures such as closing of all international borders, enactment of regional travel restrictions, closing of schools, suspension of gatherings, and implementation of physical distancing measures across the country. As of October 19, 2020, Namibia had reported 12,326 laboratory-confirmed COVID-19 cases and 131 COVID-19-associated deaths. CDC, through its Namibia country office, as part of ongoing assistance from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) provided technical assistance to the Ministry of Health and Social Services (MoHSS) for rapid coordination of the national human immunodeficiency virus (HIV) treatment program with the national COVID-19 response.
